ACE2 and COVID-19: There was a theoretical endorsement that the increase of ACE2 by the indirect effects of AngII receptor blockers (ARB) and ACE inhibitors taken by patients with CVD and related comorbidities, could enhance docking sites for SARS-CoV-2, leading to severe COVID-19 [17,18].